AR and Epstein-Barr virus infection: These preliminary findings are also supported by another recent in vitro study showing that TFM inhibited cellular proliferation, and promoted apoptosis, in EBV-transformed B cells at a clinically-relevant dose, suggesting that TFM may inhibit lytic EBV infection both by preventing the initial steps of viral reactivation and by blocking viral DNA replication, via its impact on host pyrimidine metabolism [40].